A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Stopped Lack of accrual
Conditions
- Resectable Pancreatic Cancer
Interventions
Sponsor
Rutgers, The State University of New Jersey
Collaborators
- [object Object]
- [object Object]
- [object Object]